New Delhi: Bharat Biotech’s nasal vaccine to fight COVID-19 has been cleared by regulators for Phase 2/3 trial.
According to the Ministry of Science and Technology, the Phase 1 trial of the adenoviral intranasal vaccine BBV154 among healthy volunteers aged 18 to 60 years produced encouraging results.
The first-of-its-kind vaccine to undergo human trials in India was found to be safe, immunogenic and well-tolerated in pre-clinical toxicity studies. It was also able to elicit high levels of neutralizing antibodies in animal studies, the ministry informed.
Bharat Biotech’s nasal vaccine has been supported by department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC).
“The department through Mission Covid Suraksha, is committed to development of safe and efficacious Covid-19 vaccines. Bharat Biotech’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials,” said DBT secretary Dr RenuSwarup.
Research to develop nasal sprays for use against COVID-19 is underway in a number of countries. India seems to be ahead of the race, at present.
Bhubaneswar: Unidentified miscreants allegedly attacked a man and kidnapped his female friend in Maitri Vihar…
Balasore: A young man was allegedly beaten to death on the suspicion of having committed…
Mumbai: Bollywood celebrities have often had funny, at times bizarre experiences, mostly involving hero-worshipping, demanding fans.…
Bhubaneswar: Police have arrested the owner of a Jatra (theatre) group for allegedly duping an…
Sanskriti Talwar Faridkot (Punjab): For the third consecutive year, Balwinder Singh of Mallan village in…
Bhubaneswar: Rain may play spoilsport in Christmas and New Year celebrations in Odisha as the…
This website uses cookies.